Pliant Partners with Cleveland Clinic to Find New Disease Targets for Gut Fibrosis

Pliant Partners with Cleveland Clinic to Find New Disease Targets for Gut Fibrosis
Pliant Therapeutics is starting a multi-year research collaboration with Cleveland Clinic to speed the discovery of new druggable targets for gastrointestinal fibrosis, a common gut complication in patients with inflammatory bowel disease (IBD). Fibrotic strictures in the bowel, a narrowing in the intestine which can make it difficult for food material to pass through, are often a consequence of IBD. As much as 40% of patients with ileal Crohn's disease (affecting the last part of the small intestine) will eventually have this condition. No noninvasive strategies exist to efficiently prevent or manage fibrotic strictures in the gut, which are primarily treated through surgery.  The goal of the new collaboration between Pliant and Cleveland Clinic is to find new and noninvasive therapeutic approaches that would prevent this scarring process from worsening, and improve patients' quality of life. Researchers from both institutions will collaborate to better understand the mechanisms underlying fibrosis of the gut and to look for potential druggable targets of the disease, which are largely lacking. They will work with human cells, tissues, and organ culture systems in the lab, as well as novel animal models to identify and validate new targets. The initiative will rely o
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *